GOSS

Business Context and Reporting Period

Company: Gossamer Bio, Inc. (Nasdaq: GOSS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing seralutinib, an inhaled small molecule inhibitor, for the treatment of pulmonary hypertension (PH), specifically pulmonary arterial hypertension (PAH) and PH associated with interstitial lung disease (PH-ILD). The company operates as a single segment and relies on a strategic collaboration with Chiesi Farmaceutici S.p.A. for global development and commercialization outside the U.S., while co-commercializing in the U.S.

Key Financial Metrics

Note: Revenue consists primarily of cost-sharing reimbursements and license fees from the Chiesi Collaboration Agreement. The company has no product sales revenue.

Material Changes vs. Prior Period

• Revenue Decline: Total revenue decreased by $66.2 million (58%) year-over-year. This was primarily due to the absence of the $90.7 million one-time license fee recognized in 2024, partially offset by an increase in cost-sharing revenue from Chiesi.
• Increased Net Loss: Net loss widened significantly to $170.4 million from $56.5 million, driven by higher R&D spending ($35.6 million increase) related to the Phase 3 PROSERA trial and the recognition of $7.5 million in In-Process Research and Development (IPR&D) expenses for the Respira Therapeutics option.
• Cash Position: Cash and marketable securities decreased by approximately $157.6 million, reflecting a net cash outflow from operating activities of $171.3 million, partially mitigated by net cash provided by investing activities ($156.4 million) from the maturity of marketable securities.
• Going Concern Warning: The independent auditor included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.

Guidance, Outlook, and Material Events

Clinical Trial Results (PROSERA)

In February 2026, the company announced topline results from the Phase 3 PROSERA trial for seralutinib in PAH. The study did not meet its primary endpoint of placebo-adjusted improvement in six-minute walk distance (6MWD) at Week 24 (13.3 meters; p=0.0320), missing the prespecified alpha threshold of 0.025. However, the company highlighted positive signals in intermediate- and high-risk subgroups and the connective tissue disease-associated PAH (CTD-APAH) subgroup.

Strategic Response

• Regulatory Engagement: Management plans to engage with the FDA (Type C meeting) to discuss the totality of data and potential regulatory paths forward, with a potential approval action date anticipated by year-end 2027 if an NDA is submitted.
• Workforce Reduction: In March 2026, the company announced a reduction of approximately 77 employees (48% of the workforce) to preserve cash. Estimated charges are $6.7 million.
• Paused Enrollment: Enrollment in the Phase 3 SERANATA study for PH-ILD was paused to evaluate PROSERA implications and allocate resources disciplinedly.
• Liquidity Outlook: Management believes existing cash resources will fund operations into the first quarter of 2027. The company expects to require substantial additional financing to support future development and potential commercialization.

Risks and Contingencies

• Capital Requirements: The company faces significant uncertainty regarding its ability to raise additional capital on acceptable terms. Failure to do so could force delays or termination of development programs.
• Debt Maturity: The company has $200 million in aggregate principal amount of 5.00% convertible senior notes due in May 2027. Refinancing or repayment capabilities depend on capital market conditions and the success of seralutinib development.
• Regulatory Uncertainty: The failure to meet the primary endpoint in PROSERA creates uncertainty regarding FDA approval, potentially requiring additional trials or limiting the approved indication.

Investor Verification Checklist

• Capital Runway: Verify the sufficiency of the $136.9 million cash balance to fund operations through Q1 2027 given the increased burn rate and paused revenue streams.
• FDA Feedback: Monitor the outcome of the planned Type C meeting with the FDA to determine if a viable regulatory path exists without further large-scale clinical trials.
• Debt Refinancing: Assess the company's ability to refinance or repay the $200 million convertible notes maturing in May 2027, especially given the "substantial doubt" going concern qualification.
• Subgroup Analysis: Review the detailed data for the high-risk and CTD-APAH subgroups to evaluate the potential for a restricted label approval.
• Cost Reduction Impact: Track the execution of the 48% workforce reduction and the resulting impact on the operating expense trajectory in 2026.